Medical Doctor Program year 2025 Reported 2019–2025 Source: CMS Open Payments, 2026 publication

Christopher Chang

Gastroenterology Albuquerque, NM Medical Doctor

NPI 1417981796 CMS profile 290718

1501 San Pedro Dr Se, Medicine Service, Box 111, Albuquerque, NM 87108

Open in the dashboard

General payments

$50,784

232 records reported · program years 2019–2025

Research payments

$0

Paid to them · None reported · program years 2019–2025

Ownership & investment interest

$0

None reported

Research they led as principal investigator

$59,210 paid to institutions, not to them · program years 2019–2022

Through program year 2025, Christopher Chang of Albuquerque, NM is reported in the CMS Open Payments database as having received $50,784 across 232 general payments and $0 in research payments paid to them. Separately, studies naming them as principal investigator received $59,210 in research payments, paid to institutions rather than to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them. The principal-investigator line is research money paid to institutions for studies they led — not to them — and is not added to anything either.

General payments for this record sit in the 93rd percentile of Gastroenterology profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

7 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $6,666 67
2024 General $15,376 64
2023 General $2,086 30
2022 General $5,290 15
2021 General $3,739 9
2020 General $4,592 11
2019 General $13,037 36

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Christopher Chang
  • Gastroenterology median
  • Middle half of Gastroenterology
  • National median

In program year 2025, general payments to Christopher Chang were reported at $6,666. Among 13,050 Gastroenterology profiles paid that year, the median was $639 and the middle half received between $167 and $1,700.

Show as a table
Year Christopher Chang Gastroenterology median Middle half National median
2019 $13,037 $417 $126–$1,100 $163
2020 $4,592 $224 $74–$624 $114
2021 $3,739 $352 $106–$1,054 $132
2022 $5,290 $448 $129–$1,270 $149
2023 $2,086 $533 $150–$1,390 $160
2024 $15,376 $605 $160–$1,606 $164
2025 $6,666 $639 $167–$1,700 $169

Breakdown

Who paid General payments · program years 2019–2025
  1. Salix Pharmaceuticals, a division of Bausch Health US, LLC $26,556 60 payments
  2. Aimmune Therapeutics, Inc. $12,373 15 payments
  3. Mirum Pharmaceuticals, Inc. $3,513 4 payments
  4. AbbVie, Inc. $2,602 67 payments
  5. Enterra Medical, Inc. $1,584 8 payments
  6. Ardelyx, Inc. $808 8 payments
  7. Gilead Sciences, Inc. $476 15 payments
  8. Mallinckrodt Hospital Products Inc. $416 6 payments
  9. Phathom Pharmaceuticals, Inc. $248 7 payments
  10. Ipsen Biopharmaceuticals, Inc $204 4 payments
  11. Other $2,005 38 payments

Every payment, record by record

What the payments were for General payments · program years 2019–2025
  1. Consulting Fee $14,550 4 payments
  2. Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program $11,250 2 payments
  3. Food and Beverage $11,247 214 payments
  4. Compensation for serving as faculty or as a speaker for a non-accredited and noncertified continuing education program $11,200 1 payment
  5. Travel and Lodging $2,492 9 payments
  6. Education $45 2 payments
Products named General payments · program years 2019–2025
  1. XIFAXAN $13,881 43 payments
  2. TRULANCE Gastroenterology $12,374 13 payments
  3. ZENPEP $12,089 10 payments
  4. IBSRELA $808 8 payments
  5. SKYRIZI Immunology $781 20 payments
  6. RINVOQ $751 28 payments
  7. SKYRIZI Immunology $496 23 payments
  8. TRULANCE Gastroenterology $448 5 payments
  9. TERLIVAZ $416 6 payments
  10. VOWST $300 6 payments
  11. Other $3,351 69 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Records

232 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Gastroenterology in New Mexico

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record